While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.
Mylan pushed the blame for high EpiPen prices onto PBMs Thursday, causing share prices to dip. Analysts say investors were mislead.
It took 12 months for Teva to gain FTC approval to buy Allergan's U.S. generics business. Future mergers could face the same long scrutiny.